Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solifenacin/tamsulosin - Astellas Pharma

Next Previous
Drug Profile

Solifenacin/tamsulosin - Astellas Pharma

Alternative Names: EC905; Solifenacin succinate/tamsulosin hydrochloride; Tamsulosin hydrochloride/solifenacin succinate; Tamsulosin/solifenacin; Urizia; Vesomni; Volutsa

Latest Information Update: 14 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Rovi
  • Class Amines; Antispasmodics; Benzene derivatives; Esters; Ethers; Isoquinolines; Quinuclidines; Small molecules; Sulfonamides; Urologics
  • Mechanism of Action Alpha-1a adrenergic receptor antagonists; Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Benign prostatic hyperplasia

Most Recent Events

  • 14 Feb 2019 Chemical structure information added
  • 30 Apr 2015 No recent reports on development identified - Phase-III for Benign prostatic hyperplasia in Austria, Belarus, Belgium, France, Germany, Hungary, Italy, Poland, Russia and Slovakia (PO)
  • 11 Feb 2015 Rovi acquires the marketing rights of solifenacin/tamsulosin in Spain
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top